Astrazeneca (AZN) Cash & Current Investments (2009 - 2026)

Astrazeneca's Cash & Current Investments history runs 18 years deep, the most recent figure standing at $5.0 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments fell 30.43% year-over-year to $5.0 billion; the TTM figure through Jun 2026 stood at $5.0 billion (down 30.43% YoY), while the FY2025 annual figure was $5.8 billion, up 2.6% from the prior year.
• Cash & Current Investments for Q2 2026 stood at $5.0 billion, down from $9.9 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $10.1 billion in Q3 2025, with the low at $5.0 billion in Q2 2026.
• The 5-year median for Cash & Current Investments is $6.7 billion (2023), against an average of $7.0 billion.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments sank 64.29% in 2022, then surged 52.33% in 2025.
• Astrazeneca's Cash & Current Investments stood at $6.4 billion in 2022, then declined by 6.92% to $6.0 billion in 2023, then slipped by 5.17% to $5.7 billion in 2024, then climbed by 2.6% to $5.8 billion in 2025, then slipped by 14.22% to $5.0 billion in 2026.
• Business Quant data shows AZN's Cash & Current Investments at $5.0 billion in Q2 2026, $9.9 billion in Q1 2026, and $5.8 billion in Q4 2025.